[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200605224B - Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions - Google Patents

Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Info

Publication number
ZA200605224B
ZA200605224B ZA200605224A ZA200605224A ZA200605224B ZA 200605224 B ZA200605224 B ZA 200605224B ZA 200605224 A ZA200605224 A ZA 200605224A ZA 200605224 A ZA200605224 A ZA 200605224A ZA 200605224 B ZA200605224 B ZA 200605224B
Authority
ZA
South Africa
Prior art keywords
estrogen
days
longer
period
pharmaceutical preparation
Prior art date
Application number
ZA200605224A
Other languages
English (en)
Inventor
Duesterberg Bernd
Schuermann Rolf
Endrikat Jan
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34443011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200605224(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA200605224B publication Critical patent/ZA200605224B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200605224A 2003-11-26 2006-06-23 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions ZA200605224B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090405A EP1535618A1 (en) 2003-11-26 2003-11-26 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Publications (1)

Publication Number Publication Date
ZA200605224B true ZA200605224B (en) 2009-10-28

Family

ID=34443011

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605224A ZA200605224B (en) 2003-11-26 2006-06-23 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Country Status (22)

Country Link
US (1) US20080234240A1 (xx)
EP (3) EP1535618A1 (xx)
JP (1) JP2007512291A (xx)
KR (1) KR20060126671A (xx)
CN (1) CN1905885A (xx)
AR (1) AR046671A1 (xx)
AU (1) AU2004292778A1 (xx)
BR (1) BRPI0416924A (xx)
CA (1) CA2547051A1 (xx)
CR (1) CR8450A (xx)
EA (1) EA200600964A1 (xx)
EC (1) ECSP066674A (xx)
GT (1) GT200400242A (xx)
IL (1) IL175858A0 (xx)
NO (1) NO20062945L (xx)
PA (1) PA8618301A1 (xx)
PE (1) PE20051038A1 (xx)
RS (1) RS20060348A (xx)
TW (1) TW200529862A (xx)
UY (1) UY28631A1 (xx)
WO (1) WO2005051400A1 (xx)
ZA (1) ZA200605224B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
JP2009501722A (ja) * 2005-07-15 2009-01-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ドロスピレノン含有経皮用薬剤供給装置及びその供給方法
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
WO2008018872A1 (en) * 2006-08-10 2008-02-14 Drugtech Corporation Therapeutic methods of using estrogen compositions
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
CN104546870B (zh) * 2015-01-27 2018-01-12 唐凡兰 一种避孕药
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
GEP20217308B (en) 2015-06-18 2021-10-25 Estetra Sprl Orodispersible dosage unit containing an estetrol component
DK3310346T3 (da) 2015-06-18 2021-05-25 Estetra Sprl Orodispersibel tablet indeholdende estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
CA3178291A1 (en) * 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JP2018083806A (ja) * 2016-11-11 2018-05-31 持田製薬株式会社 月経困難症治療用組成物
AU2019219070A1 (en) * 2018-02-07 2020-09-24 Estetra Srl Contraceptive composition with reduced cardiovascular effects
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969502A (en) * 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
AU630334B2 (en) * 1987-09-24 1992-10-29 Jencap Research Ltd. Hormone preparations for hormone replacement therapy and contraceptive method
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
CN1186023C (zh) * 1996-07-26 2005-01-26 惠氏公司 双相避孕方法及包含孕激素和雌激素组合物的药剂盒
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JP2001513566A (ja) 1997-08-27 2001-09-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 経口避妊における、エストロゲンと子宮内膜節約性プロゲスチンおよび子宮内膜萎縮性プロゲスチンとの組み合わせ物
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
EP1406634A1 (en) * 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
CA2468748C (en) 2001-12-05 2010-01-26 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

Also Published As

Publication number Publication date
EA200600964A1 (ru) 2006-10-27
CR8450A (es) 2007-06-06
RS20060348A (xx) 2008-08-07
EP2044942A1 (en) 2009-04-08
PE20051038A1 (es) 2006-02-08
CN1905885A (zh) 2007-01-31
BRPI0416924A (pt) 2007-01-16
TW200529862A (en) 2005-09-16
AU2004292778A1 (en) 2005-06-09
GT200400242A (es) 2006-01-18
KR20060126671A (ko) 2006-12-08
CA2547051A1 (en) 2005-06-09
US20080234240A1 (en) 2008-09-25
JP2007512291A (ja) 2007-05-17
EP1535618A1 (en) 2005-06-01
EP1689409A1 (en) 2006-08-16
ECSP066674A (es) 2006-10-25
IL175858A0 (en) 2006-10-05
NO20062945L (no) 2006-08-23
UY28631A1 (es) 2005-06-30
WO2005051400A1 (en) 2005-06-09
AR046671A1 (es) 2005-12-14
PA8618301A1 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
ZA200605224B (en) Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CY2021020I1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
HUP0202500A2 (en) Use of a pharmaceutical combination of ethinylestradiol and drospirenone for producing pharmaceutical compositions having contraceptive activity
HUP0302093A3 (en) Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy
HUP0301422A3 (en) Pharmaceutical compositions of estrogenic agents
HUP0203451A3 (en) Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
EP1648382A4 (en) HORMONE TREATMENT METHODS USING CONTRACEPTIVE DOSAGES WITH CONTINUOUS ADMINISTRATION OF ESTROGENES
HUP0401250A3 (en) Medical aerosol compositions and process for their preparation
HK1082677A1 (en) Androgen pharmaceutical composition and use for manufacture of medicament
IL200482A0 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EP1648474A4 (en) PROCESS AND PHARMACEUTICAL COMPOSITIONS FOR WOUND HEALING
ZA200700483B (en) Process for the preparation 2-substituted-derivatives of estrone and estradiol
HUP0302130A3 (en) Combination pharmaceutical compositions and process for their preparation
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
IL173148A0 (en) Methods and pharmaceutical compositions for healing wounds
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
HUP0203032A3 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use
HUE043200T2 (hu) Etinilösztradiol és klórmadinon-acetát kombinációját tartalmazó hormonális fogamzágátló
EP1857111A3 (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis
PL357020A1 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
HUP0301134A3 (en) Use of 7-hydroxyepiandrosterone having neuroprotective activity for preparing pharmaceutical compositions
IL162101A (en) Crystalline form of a ribofuranosyluronamide derivative, pharmaceutical compositions comprising it, processes for its preparation and use thereof in the preparation of medicaments
EP1807122A4 (en) MEDICAL AEROSOL FORMULATIONS AND METHOD FOR SYNTHETIZING INGREDIENTS THEREFOR
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions